Algert Global LLC Purchases 10,909 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Algert Global LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 34.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,157 shares of the company's stock after purchasing an additional 10,909 shares during the period. Algert Global LLC owned approximately 0.14% of Medpace worth $14,006,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in shares of Medpace in the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace in the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp grew its holdings in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC grew its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Finally, Assetmark Inc. grew its position in Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Transactions at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director now owns 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 20.30% of the stock is currently owned by corporate insiders.

Medpace Stock Performance

Shares of NASDAQ MEDP traded up $10.93 during trading on Wednesday, hitting $299.70. The company had a trading volume of 457,029 shares, compared to its average volume of 346,269. The business's 50-day moving average is $308.38 and its 200 day moving average is $329.37. The company has a market cap of $8.61 billion, a P/E ratio of 23.73, a PEG ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The firm had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same period in the prior year, the business earned $3.20 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Upgrades and Downgrades

MEDP has been the topic of several recent analyst reports. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Truist Financial lowered their target price on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Mizuho lowered their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Finally, TD Cowen cut Medpace from a "buy" rating to a "hold" rating and reduced their target price for the company from $370.00 to $328.00 in a report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.